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Abstract. The ‘2nd Workshop on Paediatric Virology’, which 
took place on Saturday the 8th of October 2016 in Athens, 
Greece, provided an overview on recent views and advances on 
Paediatric Virology. Emphasis was given to HIV-1 management 
in Greece, a country under continuous financial crisis, hepa-
titis B vaccination in Africa, treatment options for hepatitis C 
virus in childhood, Zika virus in pregnancy and infancy, the 
burden of influenza on childhood, hand‑foot‑mouth disease and 
myocarditis associated with Coxsackie viruses. Other general 
topics covered included a critical evaluation of Paediatric 
Accident and Emergency viral infections, multimodality 
imaging of viral infections in children, surgical approaches of 
otolaryngologists to complex viral infections, new advances in 
the diagnosis and treatment of viral conjunctivitis and novel 
molecular diagnostic methods for HPV in childhood. A brief 
historical overview of the anti-vaccination movement was also 
provided, as well as presentations on the educational challenge 
of Paediatric Virology as a new subspecialty of Paediatrics. 
This review highlights selected lectures and discussions of the 
workshop.
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1. Introduction
Paediatric Virology, which combines Paediatrics with Clinical 
Virology, is a bold, new and rapidly increasing educational 
challenge (1-4). Over the past two decades, the new advances in 
the field of Clinical Virology, as well as in Molecular Medicine, 
Epidemiology, Evidence-based Medicine, Clinical Governance, 
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Quality Improvement, Pharmacology and Immunology have 
expanded the knowledge base in viral infections occurring in 
neonates and children (2). Moreover, new vaccines and antiviral 
agents are currently under investigation and their introduction 
into clinical practice will contribute towards solving important 
public health issues in both developed and developing coun-
tries. New emerging diseases, such as Zika virus (ZV), West 
Nile virus (WNV) and Ebola virus (EV) infections, require 
new prevention strategies and therapeutic protocols, while old 
viral infections, such as poliomyelitis and hepatitis, are reap-
pearing in areas where these had been thought to be eradicated.
In addition, Paediatric Infectious Diseases (PID) profes-
sionals are often involved in the specialised care and follow-up 
of children with a history of complicated viral infections, such 
as viral meningitis, surviving to adolescent years and beyond, 
children with acquired immunodeficiency syndrome (AIDS) 
and Oncology, Neonatal Intensive Care Unit (NICU), Paediatric 
Accident and Emergency (A&E) and Paediatric Intensive Care 
Unit (PICU) patients, requiring enhanced medical care and 
innovative technological services. Moreover, recently newfound 
social issues have arisen including the anti-vaccination wave, 
the financial crisis and the unprecedented human migrations 
occurring globally and in the Mediterranean countries in 
particular (2). These developments and changes definitely 
highlight the demand for continuing education of paediatri-
cians and PID health professionals in the ongoing advances in 
the discipline of Paediatric Virology.
2. 2nd Workshop on Paediatric Virology
This is the second year that the workshop on Paediatric Virology, 
entitled ‘2nd Workshop on Paediatric Virology-Paediatric 
Virology: A rapidly increasing educational challenge’, was 
held. It was hosted at the ‘21st World Congress on Advances in 
Oncology’ and the ‘19th International Symposium on Molecular 
Medicine’, which were attended by more than 500 participants 
from five continents (5). The workshop aimed to bring together 
virologists with paediatricians and PID health professionals 
encouraging them to work together as an international network 
to achieve our goal of promoting children's health against the 
viral infectious diseases. Its educational programme tried to 
deliver a wealth of new material covering a diversity of viral 
infections occurring in infancy and childhood.
It was co-chaired by Professor Maria Theodoridou, 
Emeritus Professor of Paediatrics at the ‘Aghia Sophia’ 
Children's Hospital in Athens, Vice President of the National 
Immunisation Committee and former President of the Hellenic 
Paediatric Infectious Diseases Society (Greece), Professor Anna 
Kramvis, Research Professor of Molecular Virology and 
Director of the Hepatitis Virus Diversity Research Unit of 
the University of the Witwatersrand in Johannesburg (South 
Africa), Dr Sharryn Gardner, Paediatric A&E/Paediatric 
Consultant at Southport and Ormskirk NHS Hospital in 
Merseyside (UK) and Dr Georgia Papaioannou, Head and 
Consultant Paediatric Radiologist at the ‘Mitera’ Children's 
Hospital in Athens (Greece). The workshop was enthusiasti-
cally supported by the Department of Clinical Virology of 
the University of Crete School of Medicine (Greece), the 1st 
Department of Paediatrics at the University of Athens School 
of Medicine (Greece) and the Paediatric Virology Study 
Group (PVSG). In this review, we present an update on selected 
topics presented, discussed and evaluated at the workshop.
3. Update on current views and advances on Paediatric 
Virology
The Greek experience of HIV‑1 infection in children. The emer-
gence of human immunodeficiency virus 1 (HIV‑1) infection in 
children in 1982 was a new problem of unknown dimensions in 
all countries, worldwide (6). In childhood, the majority of HIV-1 
infections causing AIDS are acquired through mother-to-child 
transmission (MTCT) of HIV-1 during pregnancy, delivery or 
breast feeding. In Greece, the diagnoses of the first cases of 
AIDS were in multitransfused children and adolescents with 
thalassaemia and haemophilia (Fig. 1). They were infected 
prior to 1985, when HIV-1 screening and inactivation of blood 
products was initiated. The prevalence rate of HIV-1 infection 
ranged from 2 to 11% (6‑8). The size of the problem in verti-
cally infected children was unknown; however, the incidence 
of infection among women was found to be low, 1:10,000. 
Moreover, the number of infected babies was small and 
remains so with the implementation of the preventive strategy 
with zidovudine and antiretroviral treatment during pregnancy 
and the neonatal period (9). Effective prevention has reduced 
the risk of the perinatal transmission of HIV-1 to <1-2%.
In Greece, the ‘new’ infectious disease necessitated 
the establishment of a special Paediatric AIDS Unit at the 
‘Aghia Sophia’ Children's Hospital, in Athens, which became 
the national reference centre (6). The Unit had a multifac-
eted goal. The main activity was both the treatment and the 
social-psychological support of the children, their parents and 
relatives. Efforts were also made to collaborate with the AIDS 
Units for adults and the Maternity Clinics to ensure the prompt 
management of the HIV-1-positive pregnant woman and her 
newborn. All babies had a follow-up period of 2 years (10,11). 
The educational role of the Unit for healthcare personnel, 
students and the public, during a period of unreliable fears 
and prejudices, was also of great importance. In a rather short 
period of time, as a result of the scientific achievements in all 
fields, the prognosis of HIV‑1 infection has changed. HIV‑1 has 
been transformed from a progressive and often fatal infection 
to a chronic condition (12). Unfortunately, children and adoles-
cents of the initial AIDS period did not have the privilege of 
the anti-retroviral therapy. There are still a lot of challenges 
involved in the treatment of this infection and its long term 
adverse effects (13). There is also an urgent need for the devel-
opment of child-friendly medication. Moreover, HIV-1-infected 
children survive to adulthood and there are many new issues 
regarding their transition to adult care. Intensive education 
and support is important for the adherence to drug regimens, 
which will enable them to lead a good quality of life (14). The 
vision of no new HIV-1 cases can be achieved with effective 
prevention strategies for the perinatal transmission, but also 
with prevention of HIV-1 infection in youth (15).
Hepatitis B vaccination in Africa. Worldwide, there are 
240 million chronic carriers of hepatitis B virus (HBV), 
of which at least 65 million reside in Africa (16-18). In 
sub-Saharan Africa, HBV is hyperendemic and there is a 
corresponding high incidence of hepatocellular carcinoma (19). 
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In September 2015, the ‘1st World Hepatitis Summit’, held in 
Glasgow, Scotland (UK), resolved that a concerted effort 
should be taken to eradicate HBV infection globally by the 
year 2030 (20). If we desire to eradicate HBV globally by 
the year 2030, that leaves us with a period of 15 years, HBV 
research in Africa has to be given the attention it deserves. For 
far too long, HBV has been eclipsed by the ‘blockbuster’ infec-
tions that cause AIDS, malaria and tuberculosis, even though 
the global burden of HBV is equivalent to that of malaria and 
tuberculosis.
The most effective method for preventing HBV infection 
is vaccination. The hepatitis B vaccine is the first vaccine to 
act against two viruses, HBV and hepatitis D virus (HDV), 
against chronic and sexually transmitted disease and against 
cancer. The risk of chronic HBV infection is inversely 
proportional to the age at which HBV infection is acquired. 
Therefore, it is important to prevent HBV infection as early 
as possible. Although the World Health Organization (WHO) 
recommends birth dose vaccination (21), this is not imple-
mented in most African countries. Both monovalent and 
multivalent HBV vaccines are administered, usually with 
a 6-10-14-week schedule (22). Although the coverage of the 
3rd dose of the HBV vaccine has ‘caught up’ with the world 
average of 82%, it still has not reached that of other regions of 
the world, apart from Asia (23). There are regions in Africa, 
such as South Sudan, for which no data are available, as well as 
regions, where there is <50% coverage, such as Chad, Central 
African Republic (CAR) and Somalia (23). The coverage in 
the northern countries has decreased, as a consequence of the 
events of the ‘Arab Spring’. Conflicts and violence in Mali, 
Sudan, South Sudan, Cameroon, Nigeria, Chad and CAR have 
caused the displacement of large sections of the population and 
have added to the economic causes of migration from Africa, 
mainly to Europe. Thus, HBV is being carried from areas of 
high endemicity to areas of low endemicity, and the introduc-
tion of HBV to these regions, where universal vaccination is 
not generally practiced, will definitely hamper efforts for the 
global eradication of HBV.
Treatment options for hepatitis C virus in childhood. 
Hepatitis C virus (HCV) infection is a major global health 
concern (24). According to WHO, globally at least 170 million 
people are infected with HCV, accounting for 3% of the world's 
population (24,25). There is a paucity of data on its prevalence 
in children, mainly due to the lack of screening and the asymp-
tomatic course of infection in children (26). The prevalence in 
children ranges from 0.05% in developed countries to 9% in 
rural areas of Egypt, which also has the highest adult prevalence 
worldwide (27). The most common HCV strain circulating in 
children in genotype 1 (26). HCV can be transmitted iatro-
genically to children, by blood transfusions, transplantations 
and unsafe injection practices (26). However, MTCT remains 
a major route of infection and infected neonates become 
chronic carriers of HCV. The major risk factor for MTCT is 
high viral loads and elective caesarian section is recommended 
when viral loads exceed 105 IU/ml, as currently there are no 
effective methods to prevent MTCT (28). There are no recom-
mendations for the use of drugs for the prevention of perinatal 
infection (26). HCV infection is generally asymptomatic in 
childhood, with mildly abnormal transaminases and hepatic 
damage is minimal. However, fibrosis is correlated with age 
and duration of infection, thus children should be monitored 
and treated, as early as possible, to avoid disease progression.
Although the standard of care treatment regimens of 
pegylated interferon (IFN) combined with ribavirin are well 
tolerated and effective in children (28-31), they are lengthy, 
relatively toxic and expensive (Fig. 2). Fifty percent of patients 
infected with genotype 1 will not respond to this treat-
ment (30). Genotypes 2, 3 and 4 yield the optimal sustained 
virologic response (SVR) of >80% (30). In February 2016, 
WHO updated its HCV treatment guidelines (32). It was 
recommended that direct-acting antiviral (DAA) regimens 
should be used for the treatment of persons with HCV infec-
tion rather than regimens with pegylated IFN/ribavirin. DAA 
regimens target the HCV protease, polymerase and NS5A, the 
protein necessary for viral replication and assembly. Although 
animal reproduction studies have failed to demonstrate a risk 
Figure 1. Paediatric cases of HIV-1 infection by transmission group reported in Greece by 31/12/2014 - adapted from Hellenic Centre for Disease Control and 
Prevention (HCDCP) (11).
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of using currently available IFN-free treatment modalities for 
HCV to the foetus (24), to the best of our knowledge, there are 
no adequate and well-controlled studies on pregnant women 
currently available. Moreover, DAA regimens have not been 
licensed for use in children as their safety in children has not 
been determined. It is hoped that a positive outcome in pending 
clinical trials in children for IFN-free DAA regimens will revo-
lutionise therapy for HCV-infected children as they have for 
their adult counterparts (33). Moreover, if widely used, these 
DAA regimens may also contribute to eliminating MTCT.
ZV in pregnancy and in infancy. ZV is a single-stranded RNA 
virus, closely related to dengue fever, yellow fever, Japanese 
encephalitis and WNV infections (34,35). Zika is the name of 
the disease caused by this virus. The primary mode of trans-
mission is via the bite of infected Aedes aegypti and Aedes 
albopictus mosquitoes (36). Other modes of infection include 
maternal/foetal transmission (intrauterine and perinatal), sexual 
transmission and laboratory exposure (37). Outbreaks have 
occurred in 48 countries and territories (38). All age groups 
are affected, although adults are more likely to seek medical 
attention. The clinical illness is usually mild, the incubation 
period varies from 3 to 14 days and viraemia occurs for up 
to a week (39). The majority of the infections are subclinical 
and the most common clinical features include an acute onset 
of fever, maculopapular rash, arthralgia and conjunctivitis, 
although headaches and myalgia have also been reported (40). 
ZV disease during pregnancy is of particularly concern as 
foetal and perinatal transmission have been reported, causing 
microcephaly and other severe defects, including eye defects, 
hearing loss, impaired growth and foetal loss (36). Definitive 
diagnosis is based on the detection of ZV ribonucleic 
acid (RNA) in blood - serum or ideally, ethylenediaminetet-
raacetic acid (EDTA)‑treated plasma ‑ and other body fluids by 
polymerase chain reaction (PCR) (6). The most recent updated 
interim guidelines for the evaluation and management of infants 
with possible congenital ZV were published by the Centers for 
Disease Control and Prevention (CDC) in August 2016 (41).
Paediatric A&E: viral infections on the frontline. Viral infec-
tions are very common in infancy and childhood with estimates 
of between 8 and 18 infections per child per year (42,43). 
While these may sound benign or trivial, often children will 
be unwell for several days, and this thus affects on parents' 
professions and certainly sleep, as well as the child's education.
Understandably, if there is a treatment available, parents will 
be willing to make use of it. The result of better and better 
emergency facilities is parents presenting with their viral infec-
tions at an emergency service - general practitioners (GPs), 
Walk in Centres (WICs), or A&E. When diagnosed, some 
bemoan the infection being ‘just a virus’ for the tenth time as 
if they had somehow failed in the quest for the ‘magic bullet’ 
of antibiotics (44). ‘It's just a virus’ is a common complaint 
from families, and publications discuss this (45). Doctors have 
perhaps failed to express the risks of antibiotics, particularly in 
those where it is not indicated, and have not adequately chal-
lenged the mistaken view that antibiotics cure all infections. 
Emergency Departments (EDs) may not release children with 
fever and a clear focus of infection until the temperature drops, 
subconsciously giving the message that children with fever 
somehow deserve to be and indeed, should be in an ED. Doctors 
need to justify not pursuing expensive investigations and treat-
ments of clinically insignificant viral infections. Undoubtedly, 
doctors could prescribe fewer antibiotics for viral infections, 
20% of which are treated with antibiotics (46). However, only 
2/3 of urinary tract infections (UTIs) are treated acutely with 
antibiotics in a busy Paediatric ED (47). Sepsis guidelines and 
focus also suggest that doctors could improve their skills at 
identifying those who need urgent antibiotics and support (48).
The University of Utah (USA) has investigated the 
increasing amount (percentage) of time families have viruses 
detected, depending on the number of children in the home, 
from 18% in those with no children to 87% in those with 6, 
although only approximately 50% of these were found to 
produce symptoms (49). This same principle is captured in the 
phenomenon of ‘nursery syndrome’, where children in nurseries 
seem to constantly have infections, often leading to invasive 
tests as parents push for another (more sinister or medical) 
answer. The CDC has helpfully produced guidelines for when 
to investigate this (50) and a website about periodic fever is 
entitled itsnotjustavirus.com (51). Parents' views toward viruses 
are complex and often inconsistent or diametrically opposed. 
Figure 2. HCV treatment choices in children: To treat or not to treat children for HCV? - adapted from Wirth et al (30).
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The unnamed ‘just a virus’ is trivial, while life-threatening 
viruses are deemphasized in parents' desire to protect their 
child from perceived risks of mass vaccination programmes. 
Any new virus is a potential pandemic with the capacity 
to annihilate the world, forgetting that we have few viral 
treatments even for those that have been around for centuries. 
Names of these new viruses in the mass media increase this 
anxiety - ZV, EV, Nipah virus (NiV) and Hendra virus (HeV), 
for example. The perception of multiple treatments for viruses, 
such as HIV-1, may fuel this - perhaps if we carried out further 
research, we would be able to treat all viruses. Conservative 
supportive management is seen as condescending or inadequate, 
while many parents do not adequately encourage fluids intake 
or administer antipyretics regularly enough. In the future, there 
is much work to be done in both medical and public perceptions 
of viral illnesses.
Multimodality imaging of viral infections in children. 
Foetuses, infants and children are susceptible to a wide variety 
of viral infections, most commonly involving the central 
nervous system (CNS) and the chest, in greater frequency than 
adults (52). Advances in imaging modalities have enabled the 
detailed exploration of pathologies, symptoms and signs in chil-
dren starting from foetal life. Although imaging is practically 
unable to confirm the diagnosis of viral infection or identify 
the pathogen, it has the potential to accurately suggest the 
presence of a viral infection and to direct further investigations 
accordingly. Additionally, it may reveal complications of viral 
infections that may cause diagnostic uncertainty and usually 
require special treatment.
Specific imaging findings are highly suggestive for CNS 
viral infections in foetuses, infants and children, particularly 
if these infections are subdivided into the following categories: 
congenital in neonates, aseptic meningitis/encephalitis, acute 
disseminated encephalomyelitis (ADEM) in older children and 
HIV-1 infection (53). Familiarity with the clinical course, the 
route of transmission and imaging appearances usually proves 
helpful in reaching the correct diagnosis and in prompting 
timely treatment. In general, the sequelae of an intrauterine 
infection reflect a combination of the pathogens and the stage 
of foetal development at which the exposure occurred (54). 
Congenital infections occurring during the second and third 
trimester may persist in the neonate, affecting its general and 
neurologic status (54). However, as a rule of thumb, the later the 
diagnosis of congenital infections is made, the more difficult it 
is to identify the agent and the imaging findings may become 
non‑specific and less conspicuous, as incomplete white matter 
myelination may interfere with the pathology (54). In neonatal 
brain infections, magnetic resonance imaging (MRI) is the 
modality of choice even in an emergency setting (55). It accu-
rately demonstrates focal lesions, usually associated with deep 
venous infarcts, diffuse white matter oedema and/or findings of 
meningitis. With some agents, such as reactivated latent herpes 
simplex virus 1 (HSV‑1) in older children, imaging is so specific 
that it may be diagnostic: foci of haemorrhage and dystrophic 
calcification acquiring a gyriform pattern are observed both on 
computed tomography (CT) and MRI with a predilection for the 
temporal lobes (54). Additionally, recent studies support that in 
children with other causes of viral encephalitis, neuroimaging 
features may suggest the pathogens (55). In the presence of 
arterial ischaemic stroke in children, post-varicella infection 
vasculitis should be considered (56) (Fig. 3).
ADEM is a monophasic, immune mediated, inflammatory 
and demyelinating disease of the CNS with multifocal 
white matter lesions on imaging and diffuse neurological 
signs, usually presenting a short time after viral infection or 
vaccination, though in some children no associated trigger 
can be identified (57,58). The identification of typical imaging 
findings - multiple, asymmetrical areas of abnormal signal 
intensity in the white matter without contrast enhancement 
that resolve on follow-up MRI - or atypical imaging patterns 
suggestive of ADEM may enable prompt treatment, thereby 
avoiding confusion and prevent development of severe sequelae, 
improving the outcome.
The predominant radiological pattern in viral pneumonia 
in childhood is patchy areas of confluent air-space shad-
Figure 3. Post-varicella vasculitis and stroke: a 3-year-old boy presented with acute onset of left upper arm weakness and facial nerve palsy; there was a recent 
previous history of ‘gastroenteritis’. MRI performed on emergency admission revealed an extensive area of abnormal signal intensity at the region of the right 
basal ganglia on axial fluid attenuation inversion recovery (FLAIR) image (arrow in panel a), which presented restricted diffusion on diffusion weighted imaging 
(DWI) sequence (arrow in panel b) in keeping with acute ischaemic infarct. Absence of flow void on magnetic resonance angiography (MRA) was confirmed in 
the proximal part of the right anterior cerebral artery (ACA) (single arrow in c) and along the right middle cerebral artery (MCA) (double arrow in panel c).
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owing with bilateral distribution and/or interstitial pattern; 
however, lobar consolidation-especially in cases caused by the 
respiratory syncytial virus (RSV)-may be encountered (59). 
Additionally, interstitial infiltrates are seen both in viral and 
bacterial pneumonias (60). Radiological information could aid 
the differential diagnosis, management and response prediction 
in children with viral pneumonia (59). Laboratory confirmation 
of the specific causative organism is mandatory.
Viral gastroenteritis is very common in children. It does not 
often require imaging confirmation unless a complication has 
developed, i.e., intussusception, acute abdominal pain due to 
secondary appendicitis (61). In these instances, ultrasonography 
is the modality of choice to confirm the diagnosis; in the pres-
ence of intussusception, usually caused by enlarged mesenteric 
lymph nodes, radiologic air-reduction provides a minimally 
invasive treatment. In the presence of Epstein-Barr virus (EBV) 
infection ultrasonography of the abdomen may reveal coexistent 
imaging features of acalculous cholecystitis (62).
In the exploration of neck masses in children with viral 
infection, ultrasonography usually reveals typical appearances 
of reactively enlarged lymph nodes; in suspicion of EBV infec-
tion, ultrasound appearances of the affected lymph nodes may 
even suggest the pathogen - an heterogenous appearance with 
prominent lymphoid follicles (63). Post viral acute rhinosinus-
itis in children usually does not require imaging, unless there is 
clinical deterioration following initial symptom improvement; 
bacterial supra-infection is usually the underlying cause and 
cross-sectional imaging is indicated to rule-out endocranial or 
orbital extension (64). Synovitis, usually of the hip joint, is a 
not uncommon sequela of systemic viral infections. It is easily 
confirmed with hip ultrasound and usually requires no further 
imaging. However, osteomyelitis, which is a recognised but 
uncommon complication of viral infections, should be further 
investigated with MRI. A few reports of chickenpox osteomy-
elitis reveal formation of subperiosteal abscesses (65).
Influenza in childhood: a usual suspect. The global burden 
of respiratory illness in childhood is substantial and influenza 
viruses contribute to a large part of this burden (66,67). The 
disease burden in terms of high rates of infection, complications 
and hospitalisations is high, particularly during the early years 
of life. Influenza A and B virus infections are common reasons 
for hospitalisation and they are associated with substantial 
mortality in children. A global systematic analysis that used 
1982‑2012 surveillance data to provide an estimate of influ-
enza‑associated hospitalisations among children worldwide, 
revealed that there are annually 374,000 hospitalisations in chil-
dren <1 years of age, of which 228,000 are in children <6 months 
of age (68). In total 870,000 hospitalisations are estimated to 
occur annually in children <5 years (68). Influenza‑associated 
hospitalisation rates are more than three times higher in 
developing countries than in industrialised countries (68). The 
various seasonal influenza types and subtypes, such as A(H1N1)
pdm09, A(H3N2), B-Yamagata lineage and B-Victoria lineage, 
are associated with variable disease severity rates, particularly 
in the presence of underlying medical conditions, such as 
asthma, diabetes, neurological conditions, chronic lung disease 
and heart disease. The highest admission rate is found in chil-
dren <3 months of age, while children infected with influenza B 
are typically older than those infected with influenza A (69). 
Children between 5 and 59 months of age are generally consid-
ered as a high-risk group (70). In some countries, there have been 
reports of hospitalisations with severe disease associated with 
influenza A(H1N1)pdm09 infection during 2015‑2016, mainly 
at the young/middle aged adult group (70). In Fig. 4, we present 
the total number of specimens tested for influenza viruses and 
positive specimens for each influenza subtype during 2015‑2016 
in Greece according to the Hellenic Centre for Disease Control 
and Prevention (HCDCP) (71).
Rapid laboratory diagnostic methods and further genotypic 
and phenotypic analysis that are performed at the National 
Influenza Centres can assist in the timely and effective treat-
ment of the infections (71); available antiviral agents can 
substantially shorten the duration and the severity of the viral 
illness and prevent the development of bacterial complications 
when administered within the first 48‑72 h from the onset of 
Figure 4. Total number of specimens tested for influenza viruses and positive specimens for each influenza subtype during 2015‑2016 in Greece‑adapted from 
Hellenic Centre for Disease Control and Prevention (HCDCP) (71). 
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symptoms. The neuraminidase inhibitors oseltamivir and zana-
mivir lie at the front line of defense against influenza infections, 
as influenza viruses are at present widely susceptible to those 
drugs. Only 0.5% of globally circulating 2014-2015 viruses 
has been identified as resistant to those antiviral drugs (72). 
Importantly, this percentage has remained relatively stable, 
compared to influenza season 2012‑2013 and 2013‑2014 (72).
In parallel, WHO is putting a great effort into the the 
early annual prediction of circulating stains and the detection 
of antigenic variants caused by the viral antigenic drift of 
seasonal influenza viruses, in order to assist in vaccine produc-
tion. Vaccines against influenza can be administered in one 
or two doses after 6 months of age and have the potential to 
prevent infection to a great extent, depending on the circulating 
variants. The past influenza season vaccine effectiveness was 
reduced due to the circulation of B-Victoria lineage, instead of 
B-Yamagata lineage that circulated the previous seasons and 
was therefore included in the vaccine (73). For this reason, WHO 
recommended an altered composition of the 2016-2017 vaccine, 
to include B-Victoria in the trivalent vaccine. Despite the 
genetic evolution of A(H1N1)pdm09 viruses, the majority of 
6B viruses including those in newly emerging sub-subgroups, 
remain antigenically closely related to the vaccine virus (70). 
Furthermore, the low vaccine effectiveness of the LAIV vaccine 
has recently been observed in children in the USA (74), while 
these findings are not supported by the UK and Finland (75,76). 
The continuous epidemiological and virological surveillance of 
influenza viruses is essential in order to monitor and effectively 
control annual influenza outbreaks.
Neurologic manifestations of influenza in childhood. Influenza A 
infection is a common seasonal infection, resulting in a variety 
of manifestations, ranging from mild illness, such as upper 
respiratory tract infection and gastroenteritis, to severe compli-
cations, such as respiratory distress syndrome, myocarditis and 
meningoencephalitis (77-79). Neurological complications are 
well recognised in influenza infection, with different strains 
demonstrating varying degrees of neurovirulence (80-82). 
Severe neurological sequelae are more often observed following 
infection by influenza A pandemic strains (83‑85), and in 
case of the recent pandemic influenza A(H1N1)pdm09 infec-
tion represented the most severe consequence of influenza in 
children second only to death (86). The neurologic sequelae of 
influenza A infection in children vary greatly. In the most recent 
influenza outbreaks, the two most common neurologic compli-
cations reported were seizures (both febrile and non‑febrile) (87) 
and encephalopathy (88). Other less common complications 
included neuropsychiatric manifestations, stroke (89), focal 
neurologic deficits (88,90), Guillain‑Barré syndrome (91) and 
ADEM (88). The link between seizure onset and influenza infec-
tion is currently well characterised, yet modestly understood. 
It is believed that A(H1N1)pdm09 infection plays a role in the 
aetiology of febrile convulsions through a molecular cascade, 
involving neurotropic cytokines (92), the degree of fever per se, 
an unrecognised mild viral encephalitis or toxic encephalopathy 
and a potential reactivation of latent human herpes virus 6 
(HHV-6) infection (93).
Approaches of otolaryngologists for complex viral infections. 
Viral infections of the upper airway tract are quite common in 
children and infants (94). They can cause various symptoms 
and they rarely demand surgical intervention. In certain cases 
though, viral infections can cause lesions that need to be surgi-
cally removed or treated. Differential diagnostic difficulties 
may also lead to surgical intervention by the head and neck 
surgeon (aspiration for biopsy and endoscopy). The viruses 
responsible for such lesions are usually human papilloma-
virus (HPV), RSV and HSV-1.
HPV subtypes 6 and 11 cause papillomas, which can some-
times lead to an obstruction of the airway tract, particularly 
in infants and can even be fatal (95). Vertical MTCT of HPVs 
during birth is well recognised. HPVs can be found in the oral 
cavity, the pharyngeal wall and larynx, while recurrent lesions 
are common occurrences. Oral squamous papillomas are 
benign lesions, which can be found as a papillary or verrucous 
exophytic masses. These lesions are often asymptomatic and 
have limited progression. Current surgical treatment includes 
classic endoscopic surgery (cold steel removal), transoral laser 
microsurgery (TLM) using CO2 laser and microdebriders. 
Surgical removal by curettage or cautery have good success 
rates of 65-85%, but scarring and recurrence can occur in 
up to 30% of cases. The erbium-doped yttrium aluminium 
garnet (Er:YAG) laser has a small zone of thermal damage, 
allowing more precise thermal ablation with less scarring. 
Neodymium-doped yttrium aluminium garnet (Nd:YAG) laser 
light can be used through fiberoptics in a flexible probe along 
with the suction channel to treat recurrent respiratory papilloma-
tosis (RRP) caused by HPV 6 and 11 in children (96). The most 
commonly used method nowadays for the surgical treatment 
of such lesions is TLM. This method has several advantages 
including successful haemostasis, wound sterilisation and is 
devoid of sutures, while it minimises post-operative pain (97). 
Official guidelines and recommendations for the treatment of 
HPV lesions vary with the site and type of wart (98).
Acute laryngotracheitis is also a common clinical condition 
found in children (94). The aetiology is mostly viruses, such as 
parainfluenza viruses 1, 2 and 3, RSV, influenza virus, human 
adenovirus and less commonly HSV-1. This condition may lead 
to the sudden obstruction of the upper airway tract and may 
demand the intervention of the otolaryngologist to perform 
tracheostomy, when intubation is not possible (99). RSV is a 
common cause of respiratory infections and airway distress 
in young children. Hospitalisation is required in 1 and 2% 
of infected children, while almost 8% of those children that 
have been hospitalised will eventually require mechanical 
ventilation. The otolaryngologist's role is to preserve an open 
airway tract performing tracheostomy, when necessary (100). 
In certain cases, a viral infection can lead to the formation of a 
neck abscess, when bacterial co-infection is also involved. This 
rare occurrence requires the otolaryngologist's surgical inter-
vention (incision-and-drainage) in order to treat the abscess 
using a needle or steel. Non-treated abscesses can lead to 
serious complications such as sepsis, mediastinitis, necrotizing 
fasciitis and airway obstruction (101). The paediatrician's role 
is the most important in order to provide the correct diagnosis. 
Paediatricians and otolaryngologists must cooperate to ensure 
the patient's safety and successful treatment.
New advances in viral conjunctivitis. Conjunctivitis is the 
inflammation and erythema of the conjunctiva, secondary to 
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infection - viral or bacterial - or allergic reaction (102-104). 
It may present with burning, stinging, ocular discharge, 
foreign body sensation and eyelid swelling. Viral aetiology 
in children may account for up to 50% of all cases (102-106). 
Most commonly, viral conjunctivitis is caused by human 
adenovirus, which may involve upper respiratory infection and 
gastroenteritis. Epidemic keratoconjuctivitis, a highly conta-
gious infection is due to adenovirus serotypes 18, 19 and 37, 
is associated with follicles, pre-auricular lymphadenopathy, 
periorbital pain and diffuse superficial keratitis. Complications 
include persistent sub-epithelial cornea opacities, conjunctival 
scar formation and vision glare. Topical steroid drops are then 
needed to be judiciously administered and treatment may 
continue for months (102-105). Pharyngoconjuctival fever 
is another category of conjunctivitis caused by adenovirus 
serotypes 3 or 7. It presents with subconjunctival haemorrhage, 
oedema, lid swelling, watery discharge, sores and fever, follic-
ular conjunctival reaction and preauricular lymphadenopathy. 
Treatment is supportive and the infection lasts for a couple of 
weeks, while the cornea is usually not involved in the infection. 
Herpes conjunctivitis is more commonly unilateral and the 
typical herpetic eyelid vesicles help to identify the cause. There 
is conjunctival redness, discomfort and foreign body sensation. 
Cornea epithelial disease is marked by dendritic ulcers. HSV-1 
is the cause of primary eye infection. Treatment involves 
acyclovir drops 5 times/day or trifluridine 1% 6 drops/day for 
2 weeks. The debridement of the infected area of the cornea is 
also considered. Oral acyclovir has been shown to reduce the 
recurrences of herpetic epithelial keratitis/iritis if used prophy-
lactically (102-106).
HSV-2 is associated with neonatal eye infections and 
it is congenital. It may be complicated by dendriform or 
geographic keratitis. Diagnosis is clinical, but in atypical cases 
enzyme‑linked immunosorbent assay (ELISA) testing can 
confirm the diagnosis. Varicella‑zoster virus (VZV) is a herpes 
virus causing the characteristic exanthema of chickenpox, mild 
conjunctivitis, and rarely, keratits and iritis. Ocular involve-
ment is often mild and self-limited; however, topical antibiotic 
drops may prevent a secondary infection. Reactivation of a 
latent VZV from dorsal root and cranial nerve ganglia causes 
the zoster infection and conjunctivitis/keratitis /iritis may 
occur, most likely if the nasocilliary branch of the V1 nerve is 
affected (103,104,107). Infectious mononucleosis is caused by 
EBV with fever, lymphadenopathy and often mild conjunctivitis, 
which tend to be self‑limited. Influenza, mumps and rubeola are 
other causes of viral conjunctivitis and the diagnosis is clinical. 
Treatment is supportive with cool compresses on the eyelids 
and topical antibiotics (108,109). Enterovirus serotype 70 is 
the most common cause of a highly contagious conjunctivitis, 
which is usually described as acute haemorrhagic conjunctivitis. 
Infection often becomes symptomatic within one day, lasts for 
a week and causes characteristic painful subconjunctival haem-
morhages. While the prognosis for the child's vision is usually 
good, cornea microbial superinfections may occur. Molluscum 
contagiosum is caused by a deoxyribonucleic acid (DNA) 
pox virus and presents as ubiligated skin lesions perioculary. 
Lesions near the eyelid margin may cause chronic follicular 
conjunctivitis and may require surgical excision (107). Overall, 
conjunctivitis is very common among children with various 
aetiologies and similar clinical presentation. The proper use 
of antibiotics, antiviral or steroid drops is the most effective 
method to manage infection and increase patient satisfaction.
Onychomadesis and hand‑foot‑mouth disease (HFMD). 
Onychomadesis is the complete shedding of the nails from the 
proximal portion, due to temporary arrest of the function of 
the nail matrix (110). It is a rare disorder in children and the 
prolonged insult to the nail matrix may be due to local trauma 
(e.g., manicure, onychotillomania and ill‑fitting footwear), local 
cutaneous disease (dermatitis, paronychia), drugs (retinoids, 
chemotherapy agents), pemphigus, Kawasaki disease and viral 
infections. Recently, it has been recognised as a complica-
tion in the course of the common viral infection of HFMD. 
The association between onychomadesis and HFMD was 
first reported by Clementz and Mancini (111) in 2000 and by 
Bernier et al (112) in 2001.
HFMD is a highly contagious viral infection that occurs 
mainly in summer and early autumn. It presents with a sore 
throat and mouth pain and is characterised by enanthema, 
exanthema (macular, maculopapular, or vesicular) that involves 
the dorsum of the fingers and toes, the interdigital area, palms, 
soles, upper thighs and arms. It is mainly due to Coxsackie 
virus (CV) A16 and A71 (113,114). Since 2008, the epidemics 
in Europe and Asia, and in 2011 in the USA, were attributed 
to a new genotype, CV A6 (115,116). This genotype is respon-
sible for atypical and more serious manifestations, such as 
higher fever, wider distribution of the lesions (involvement of 
the extremities, face, lips, perioral area, buttocks, groin and 
perineum), more extensive skin involvement (vesiculobullous 
lesions, bullae, ulcerations, eschar formation) and longer 
duration (mean duration 12 days) (117,118). Moreover, rare 
complications have been also described, such as palmar and 
plantar desquamation one to three weeks after HFMD and nail 
disorders, beau lines and onychomadesis one to two months 
following HFMD (119). To date, the exact pathophysiological 
mechanism of nail shedding has not been elucidated (119). 
Biopsies of HFMD vesicular lesions reveal loose strands of 
fibrin, lymphocytes, monocytes and neutrophils within vesic-
ular fluid. Extensive acantholysis with reticular degeneration 
is detected in the overlying epidermis, along with perivascular 
foci of lymphocytic, monocytic and neutrophilic leukocytes 
in the upper dermis (120). Although there are some publica-
tions describing onychomadesis related to CV A6 infection, no 
clear correlation between the virus type and HFMD-related 
nail changes has been demonstrated (119,121). The diagnosis 
is made based on the characteristic clinical manifestations and 
very rarely is there a need for confirmation using PCR detec-
tion from throat, stool and vesicular fluid samples. Nucleic acid 
amplification is preferred to cell culture due to increased sensi-
tivity. There is no specific antiviral therapy for the treatment 
of enteroviruses and management is mainly supportive. The 
clinical course of HFMD is mild and complete resolution of 
symptoms and signs typically occurs within 7-10 days. Severe 
disease with neurologic or cardiovascular complications 
(encephalitis, meningitis, flaccid paralysis, myocarditis) is seen 
after CV A71 infection. It is important that the paediatricians 
become familiar with the rare complications of the disease, 
such as onychomadesis, as they may become evident weeks or 
even months later, and thus do not appear to be related to the 
original disease.
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Viral myocarditis in children. CVs belong to a family of 
non-enveloped RNA viruses, Picornaviridae and the genus 
Enterovirus, which also includes poliovirus and echo-
virus (122). They are named after the town Coxsackie in 
New York, where they were discovered. CVs are divided into 
two major subgroups, labeled A and B. Type A viruses usually 
cause only enteric diseases, while type B viruses can cause 
serious diseases beyond the intestinal tract, such as pharyngitis, 
myalgia, meningitis and myocarditis (122-124). Myocarditis is 
an inflammation of the myocardium that triggers an immune 
response, which results in myocardial oedema, necrosis and 
apoptotic degeneration of the cardiac myocytes with the subse-
quent impairment of systolic and diastolic function. Clinically, 
the manifestation of myocarditis is relatively uncommon 
in infants and children. The subclinical presentation of the 
disease is much more prevalent (125). Children affected by 
myocarditis typically present with sinus tachycardia and gallop 
rhythm on auscultation, cardiomegaly on chest X-ray and 
small voltages on the electrocardiogram (ECG). The presence 
of arrhythmia in the context of a febrile illness should point 
the clinician to the possibility of myocarditis. Paroxysmal 
atrial tachycardia (126), ventricular ectopy (127-129) and 
various degrees of heart block (130) have all been described 
in association with MC. Echocardiography often reveals 
impaired left ventricular contractility-left ventricular ejection 
fraction (LVEF) <50%, and a certain degree of mitral regur-
gitation due to mitral annulus dilatation or leaflet dysfunction. 
Pericardial effusion may be also present. Symptoms of 
myocarditis may include fever and malaise, with the addition of 
non‑specific chest pains that may be due to possible associated 
pleural or pericardial inflammation. In most cases, the disease 
is resolved spontaneously without any treatment. However, in 
approximately 20% of cases, there can be extensive damage 
to the the heart, causing arrhythmias, severe left ventricular 
dysfunction and, in more severe cases, heart failure requiring 
heart transplantation. Oxygen, diuretics and inotropic agents, 
such as dopamine or dobutamine, may be needed and the 
administration of these drugs requires admission to PICU with 
intravascular blood pressure monitoring. Digitalis should be 
used with extreme care during the acute phase of the disease 
as its enhanced activity on the inflammed myocardium can 
precipitate serious arrhythmia (131). If myocarditis results in 
dilated cardiomyopathy and chronic heart failure, digoxin and 
an angiotensin‑converting enzyme inhibitor are therapeutically 
useful (132). Even in non-complicated forms of myocarditis, 
when the course of the disease is benign, patients must undergo 
follow-up clinical and echocardiographic examinations and 
terminate any physical activity for at least 6 months following 
infection.
Novel molecular diagnostic methods of HPV in childhood. 
HPVs are small double-stranded DNA viruses that comprise 
a heterogeneous family, which consists of >130 different HPV 
types (133,134). HPVs are associated with a wide range of cuta-
neous and mucosal infections in childhood, including common 
warts, genital warts, RRP, low-grade and high-grade squamous 
intraepithelial lesions (SILs), anal cancer, vaginal cancer and 
cervical cancer (134). Different HPV types have different 
biological, molecular and chemical properties (135). Based on 
their association with cervical cancer, HPV types are classified 
as ‘high-risk’ or ‘low-risk’ (136). In infancy and childhood, 
HPV infection involves skin warts, genital warts and juvenile 
RRP among both male and female neonates and children, 
as well as cervical SILs among adolescent girls. The recently 
introduced HPV vaccination is expected to limit ‘high-risk’ 
HPV-related infections; however, HPV infections will continue 
to affect children.
Several molecular assays are available for the detection of 
HPV infection in tissue and exfoliated cell samples and they 
present different sensitivities and specificities. These methods 
can be divided into the following assays: target amplification 
assays, including PCR and in situ PCR; direct hybridisation 
assays, such as Southern transfer hybridisation (STH), dot blot 
hybridisation (DBH) and in situ hybridisation (ISH); and signal 
amplified hybridisation assays, such as hybrid capture (HC) 
assays [reviewed by Mammas et al (137)]. HPV detection by 
PCR is the most widely used method and it can be performed 
either using type-specific primers or by consensus/general 
PCR primer pairs, such as the GP5+/6+ and MY09/11 primer 
pairs, or a combination of various non-degenerate primers 
containing inosine. The PCR amplicons can be either digested 
with restriction enzymes [restriction fragment length poly-
morphism (RFLP) analysis] and analysed by agarose gel 
electrophoresis, detected using a mixture of type-specific 
probes in an enzyme immunoassay, such as the HPVDNAChip 
and the APTIMA(R) HPV assay, or sequenced and compared 
to the GenBank sequences using BLAST (138). Novel real-time 
PCR methods, such as GenoID real-time PCR assay, Abbott's 
RealTime High Risk HPV assay, or the PreTect HPV-Proofer 
can provide high-throughput results (139,140). The low 
sensitivity of STH and ISH assay can now be overcome with 
the INFORM HPV 3 and HPV-CARD assays, which show 
improved sensitivity (141,142). HC 2 is the most reliable 
signal amplified hybridisation assay, with excellent sensitivity. 
Roche's Molecular Systems Amplicor HPV MWP assay and 
the CLART HPV 2 system also exhibit increased sensitivity 
and specificity (143).
A brief historical overview on the anti‑vaccination move‑
ment. The opposition against vaccinations has its origin in the 
19th century (144). Even before Edward Jenner's work, argu-
ments against inoculation were set mostly by theologists, such as 
Reverend Edward Massey in 1722, who preached that diseases 
were sent by God to punish sin and that any attempt to prevent 
smallpox via inoculation was a ‘diabolical operation’ (144). 
The first Vaccination Act in England was passed in 1840. It 
introduced vaccination with vaccines developed from cow pox 
or vaccinia virus, but outlawed variolation, which had preceded 
vaccination, due to its greater risks (145). Thirteen years later, 
the 1853 Act enacted vaccination of all children at birth and 
added that parents or guardians, who failed to comply, would 
be strictly punished and even prosecuted (144,145). In 1867, the 
law extended the requirement to 14 years of age and its oppo-
nents argued upon individual freedom, which led eventually 
to a new law in 1898, that allowed for conscientious objection 
to compulsory vaccination. Vaccination practice in mid-19th 
century (arm-to-arm vaccination) carried substantial risks and 
the instruments used could contribute to severe adverse reac-
tions (146). Alfred Russel Wallace (1823-1913), an explorer 
and co-discoverer of the principle of natural selection, along 
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with other spiritualists, such as William Tebb (1830-1917) a 
radical liberal, founded the London Society for the Abolition 
of Compulsory Vaccination. Wallace had received vaccinations 
as a young man and all his 3 children were also vaccinated 
as well; however, it was the mandatory characteristic of the 
Act that motivated his social reformism. Although he was 
convinced that smallpox was a contagious disease, he also 
believed in a holistic view of health; thus, he claimed that 
differences in susceptibility could be caused by nutritional or 
sanitary deficiencies that contribute to the epidemiology of 
the diseases. Along with Tebb, they argued that liberty and 
science need to be taken into account; nevertheless liberty is 
far more important (145). However, at that time, Medicine and 
Pharmacology were in a pre‑scientific level and hygiene was 
quite absent as well.
Immunisation in our days has proven to be one of the 
most important and cost-effective interventions in Public 
Health (147). Diseases, such as smallpox belong to history and 
vaccinated children protected against polio, measles, menin-
gitis and other serious and sometimes fatal conditions (148). 
Thus, most parents and children have not experienced many 
of the vaccine-preventable diseases. Moreover, by not being 
well informed about the risks and sequelae of these condi-
tions (149,150), they are vulnerable to statements that lack 
scientific evidence, as it was with Andrew Wakefield's 
theory that linked vaccination against measles mumps and 
rubella (MMR) with autism in 1998. Wakefield's theory was 
deemed responsible for the decrease in immunisation rates in 
the UK from 92% to below 80% after the publication of his 
study (144).
Anti-vaccination arguments in the 21st century are often 
similar to those of 19th century, although they are spread 
mostly through the internet, where inaccurate data through 
blogs and fora increase vaccine rejection (147). Mainstream 
Medicine is questioned as well, and the use of complementary 
and alternative Medicine becomes increasingly popular (151). 
Some of the complementary and alternative therapies, such 
as homeopathy and chiropractice, are opposed to immunisa-
tions (152,153). Constantine Hering (1800-1880), who is the 
‘father of American homeopathy’, was the first homeopath, 
who declared his opposition to vaccination, which he termed 
‘poisoning’. A great deal of time must be dedicated by 
paediatricians and health organisations, in conjunction with 
government agencies such as CDC, to communicate effectively 
with parents and reliably inform them about the overall safety 
and efficacy of the vaccines. Web projects are increasingly 
being created by responsible and scientifically appropriate 
individuals, in order to counteract the misinformation on the 
web regarding vaccinations, through a series of information 
tools, such as scientific articles, educational information, 
video and multimedia presentations (147). Evidence-based 
proof, honest interest for an in depth dialogue through modern 
and everyday means of communication, such as social media 
and internet in general, is probably the best way to overcome 
vaccinophobia.
The educational challenge of Paediatric Virology. Paediatric 
Virology has been recently proposed as a new subspecialty 
candidate of Paediatrics (1). According to this proposal, 
Paediatric Virology trainees should gain valuable both clinical 
and research experience in the prevention and treatment of viral 
infections in neonates and children. It has been suggested that 
their training should be based on involvement in the clinical 
assessment, care and therapeutic management of hospitalised 
neonates and children with uncommon, recurrent, severe or 
complex viral infections. After their qualification, Paediatric 
Virology subspecialists are expected to play a multi-task role, 
not only in the university-based research and educational 
settings, but also in primary, secondary and tertiary services 
and the community (154).
Since the ‘1st Workshop on Paediatric Virology’, held 
in Athens, Greece, on Saturday the 10th of October, 2015, 
Paediatric Virology has attracted the critical interest of several 
worldwide experts in the scientific fields of Neonatology, 
Paediatrics, Clinical Virology and PID (3). These experts 
have enthusiastically offered their valuable input to the debate 
of the potential strategically principal role of Paediatric 
Virology subspecialtists into clinical practice. This debate 
has already identified well defined challenges, difficulties 
and limitations to the role of Paediatric Virology as a sepa-
rate subspecialty (154,155). However, the potential value of 
Paediatric Virology training has undoubtedly been accepted 
and its official recognition remains to be further evaluated 
by the key worldwide scientific and academic stakeholders of 
Neonatology, Paediatrics, PID and Clinical Virology.
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